Rüdiger Smolnik

1.6k total citations · 1 hit paper
22 papers, 901 citations indexed

About

Rüdiger Smolnik is a scholar working on Cardiology and Cardiovascular Medicine, Endocrine and Autonomic Systems and Nutrition and Dietetics. According to data from OpenAlex, Rüdiger Smolnik has authored 22 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrine and Autonomic Systems and 5 papers in Nutrition and Dietetics. Recurrent topics in Rüdiger Smolnik's work include Atrial Fibrillation Management and Outcomes (11 papers), Cardiac Arrhythmias and Treatments (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Rüdiger Smolnik is often cited by papers focused on Atrial Fibrillation Management and Outcomes (11 papers), Cardiac Arrhythmias and Treatments (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Rüdiger Smolnik collaborates with scholars based in Germany, Belgium and Spain. Rüdiger Smolnik's co-authors include Jan Born, Paul‐Egbert Reimitz, Horst L. Fehm, Andreas Goette, Wolfgang Zierhut, Pascal Vranckx, Jan G.P. Tijssen, Lars Eckardt, Marco Valgimigli and Thorsten Lewalter and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and European Heart Journal.

In The Last Decade

Rüdiger Smolnik

21 papers receiving 870 citations

Hit Papers

Edoxaban-based versus vitamin K antagonist-based antithro... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
    2019 383 citations Pascal Vranckx, Marco Valgimigli et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rüdiger Smolnik Germany 13 595 175 131 97 96 22 901
Jeremy Stone United States 13 27 0.0× 87 0.5× 72 0.5× 41 0.4× 79 0.8× 20 650
Arianna De Lalla Italy 15 51 0.1× 7 0.0× 37 0.3× 16 0.2× 53 0.6× 20 465
Gülay Kenangıl Türkiye 12 35 0.1× 44 0.3× 24 0.2× 22 0.2× 22 0.2× 39 475
Gian Carlo Andrioli Italy 13 137 0.2× 298 1.7× 10 0.1× 5 0.1× 156 1.6× 19 891
J. L. Elghozi France 10 274 0.5× 66 0.5× 33 0.3× 48 0.5× 18 585
Victor Zibara Lebanon 5 47 0.1× 7 0.0× 24 0.2× 10 0.1× 20 0.2× 13 486
Carolyn M. Coyne United States 8 87 0.1× 5 0.0× 42 0.3× 5 0.1× 40 0.4× 11 396
K. Iitake Japan 11 141 0.2× 68 0.5× 21 0.2× 27 0.3× 26 449
Clare J. Ray United Kingdom 13 287 0.5× 2 0.0× 173 1.3× 6 0.1× 25 0.3× 25 588
G. L. Pennington Australia 9 223 0.4× 210 1.6× 35 0.4× 58 0.6× 9 556

Countries citing papers authored by Rüdiger Smolnik

Since Specialization
Citations

This map shows the geographic impact of Rüdiger Smolnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rüdiger Smolnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rüdiger Smolnik more than expected).

Fields of papers citing papers by Rüdiger Smolnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rüdiger Smolnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rüdiger Smolnik. The network helps show where Rüdiger Smolnik may publish in the future.

Co-authorship network of co-authors of Rüdiger Smolnik

This figure shows the co-authorship network connecting the top 25 collaborators of Rüdiger Smolnik. A scholar is included among the top collaborators of Rüdiger Smolnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rüdiger Smolnik. Rüdiger Smolnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kirchhof, Paulus, Ameet Bakhai, Carlo de Asmundis, et al.. (2024). Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study. International Journal of Cardiology. 408. 132118–132118. 1 indexed citations
2.
Moreno, Raúl, Rüdiger Smolnik, Luis Nombela‐Franco, et al.. (2024). Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. Clinical Research in Cardiology. 114(3). 313–322. 1 indexed citations
3.
Kirchhof, Paulus, Ameet Bakhai, Joris R. de Groot, et al.. (2023). Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study. European Heart Journal. 44(Supplement_2).
4.
Gouni‐Berthold, Ioanna, Konstantinos C. Koskinas, Maurizio Averna, et al.. (2023). Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS German cohort. European Heart Journal. 44(Supplement_2). 3 indexed citations
5.
Goette, Andreas, Lars Eckardt, Marco Valgimigli, et al.. (2020). Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. Clinical Research in Cardiology. 110(6). 831–840. 12 indexed citations
6.
Vranckx, Pascal, Marco Valgimigli, Lars Eckardt, et al.. (2020). Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. European Heart Journal. 41(47). 4497–4504. 19 indexed citations
7.
Hohnloser, Stefan H., A. John Camm, Riccardo Cappato, et al.. (2019). Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal. 40(36). 3013–3021. 102 indexed citations
8.
Vranckx, Pascal, Marco Valgimigli, Lars Eckardt, et al.. (2019). Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet. 394(10206). 1335–1343. 383 indexed citations breakdown →
9.
Hohnloser, Stefan H., A. John Camm, Riccardo Cappato, et al.. (2018). Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE‐AF study.. Clinical Cardiology. 41(4). 440–449. 8 indexed citations
10.
11.
Bramlage, Peter, Reinhard G. Ketelhut, Eva‐Maria Fronk, et al.. (2014). Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. Clinical Drug Investigation. 34(6). 403–411. 18 indexed citations
12.
Hallschmid, Manfred, Rüdiger Smolnik, G.P. McGregor, Jan Born, & Horst L. Fehm. (2006). Overweight Humans Are Resistant to the Weight-Reducing Effects of Melanocortin4–10. The Journal of Clinical Endocrinology & Metabolism. 91(2). 522–525. 29 indexed citations
13.
Fischer, Stefan, et al.. (2003). Melatonin Acutely Improves the Neuroendocrine Architecture of Sleep in Blind Individuals. The Journal of Clinical Endocrinology & Metabolism. 88(11). 5315–5320. 22 indexed citations
14.
Smolnik, Rüdiger, Stefan Fischer, Johann Hagenah, et al.. (2002). Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease. Psychopharmacology. 161(1). 70–76. 11 indexed citations
15.
Perras, Boris, Rüdiger Smolnik, Horst L. Fehm, & Jan Born. (2001). Signs of sexual behaviour are not increased after subchronic treatment with LHRH in young men. Psychoneuroendocrinology. 26(1). 1–15. 6 indexed citations
16.
Smolnik, Rüdiger, et al.. (2001). The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4–10Decreases Body Fat in Humans1. The Journal of Clinical Endocrinology & Metabolism. 86(3). 1144–1148. 97 indexed citations
17.
Fehm, Horst L., Boris Perras, Rüdiger Smolnik, Werner Kern, & Jan Born. (2000). Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology?. European Journal of Pharmacology. 405(1-3). 43–54. 58 indexed citations
18.
Smolnik, Rüdiger, Boris Perras, Matthias Mölle, Horst L. Fehm, & Jan Born. (2000). Event-Related Brain Potentials and Working Memory Function in Healthy Humans After Single-Dose and Prolonged Intranasal Administration of Adrenocorticotropin 4-10 and Desacetyl-α-Melanocyte Stimulating Hormone. Journal of Clinical Psychopharmacology. 20(4). 445–454. 17 indexed citations
19.
Smolnik, Rüdiger, Matthias Mölle, Horst L. Fehm, & Jan Born. (1999). Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4–10 and Desacetyl-α-MSH in Humans. Neuroendocrinology. 70(1). 63–72. 23 indexed citations
20.
Smolnik, Rüdiger, Reinhard Pietrowsky, Horst L. Fehm, & Jan Born. (1998). Enhanced Selective Attention After Low-Dose Administration of the Benzodiazepine Antagonist Flumazenil. Journal of Clinical Psychopharmacology. 18(3). 241–247. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeremy Stone Breakdown of academic impact, for papers by Arianna De Lalla Breakdown of academic impact, for papers by Gülay Kenangıl Breakdown of academic impact, for papers by Gian Carlo Andrioli Breakdown of academic impact, for papers by J. L. Elghozi Breakdown of academic impact, for papers by Victor Zibara Breakdown of academic impact, for papers by Carolyn M. Coyne Breakdown of academic impact, for papers by K. Iitake Breakdown of academic impact, for papers by Clare J. Ray Breakdown of academic impact, for papers by G. L. Pennington
Rankless by CCL
2026